A carregar...
Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy
Tumor-specific monoclonal antibodies (mAbs) have demonstrated efficacy in the clinic, becoming an important approach for cancer immunotherapy. Due to its limited expression on normal tissue, the GD2 disialogangloside expressed on neuroblastoma cells is an excellent candidate for mAb therapy. In 2015...
Na minha lista:
| Publicado no: | Immunotherapy |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Future Medicine Ltd
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5619016/ https://ncbi.nlm.nih.gov/pubmed/27485082 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/imt-2016-0021 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|